Contact Us
Schwab Client Login
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spruce Biosciences, Inc. - Common Stock (NQ:SPRB)

43.56 -1.98 (-4.35%)
Delayed Quote Updated: 12:30 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Spruce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Launch of MPS3BStudy.com
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Joins the Russell 3000® Index
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences to Participate in Upcoming Conferences in June
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences to Present at Upcoming Investor Conferences in March
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces $50.0 Million Private Placement Financing
From Spruce Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.